A comparative study of in silico prediction of pKa
- C Matijssen1
© Matijssen; licensee BioMed Central Ltd. 2010
Published: 04 May 2010
The ionization constant (pKa) is the measure of the strength of an acid or base in a solution. Most ligands act as a weak acid or base. Accurate determination of pKa is important as it can improve the pharmaceutical properties of a compound . In general, charged compounds have better solubility, but are less effective in membrane permeation. Therefore, optimization of the pharmacokinetic profile of a compound can be performed by increasing or decreasing its ionization by changing functional groups. Another role for optimization of the charged group could be the interaction with its target. Changing the charge on the functional group could improve the interaction with its associated target and result in improved binding affinity.
Different methods have been developed for the computational determination of pKa values. These can be based on different methods such as QSAR  or quantum chemistry approaches . These two methods differ considerable in terms of computational resource and hence, the time needed for a prediction. Depending on the number of ligands that needed prediction and time available, a choice for one method can be made.
A comparison between several pKa predictors (Pipeline Pilot, Moka, Epik and Jaguar) was made. All methods perform well when a diverse set of ligands which covers a range of pKa values is considered. However, when optimizing a series of compounds the influence of small changes to the molecule and its effect on pKa becomes more difficult to predict.
- Waterbeemd van de H, Gifford E: Nature Rev Drug Disc. 2003, 2: 192-10.1038/nrd1032.View ArticleGoogle Scholar
- Milletti F, Storchi L, Sforna G, Cruciani G: J Chem Inf Model. 2007, 47: 2172-10.1021/ci700018y.View ArticleGoogle Scholar
- Kinsella GK, Rodriguez F, Watson GW, Rozas I: Bioorg Med Chem. 2007, 15: 2850-10.1016/j.bmc.2007.02.026.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd.